Aktionsplan Adynxx Inc
Erweiterter Zeitplan
Einfaches Diagramm
Über das Unternehmen
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
| ISIN |
US00784D1037 |
| Industry |
Biotechnology |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.adynxx.com
|
| Preisänderung pro Tag: |
0% (0.0001) |
| Preisänderung pro Woche: |
0% (0.0001) |
| Preisänderung pro Monat: |
0% (0.0001) |
| Preisänderung über 3 Monate: |
0% (0.0001) |
| Preisänderung über sechs Monate: |
0% (0.0001) |
| Preisänderung pro Jahr: |
0% (0.0001) |
| Preisänderung über 3 Jahre: |
-99.76% (0.0411) |
| Preisänderung über 5 Jahre: |
-100% (2.48) |
| Preisänderung über 10 Jahre: |
0% (0.0001) |
| Preisänderung seit Jahresbeginn: |
0% (0.0001) |
|
|
Unterschätzung
| Name |
Bedeutung |
Grad |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
0 |
0 |
| Gesamt: |
|
2.5 |
|
Effizienz
| Name |
Bedeutung |
Grad |
| ROA, % |
0 |
0 |
| ROE, % |
0 |
0 |
| Gesamt: |
|
0 |
|
|
|
Dividenden
| Name |
Bedeutung |
Grad |
| Div yield, % |
0 |
0 |
| DSI |
0.5 |
5 |
| Gesamt: |
|
2.35 |
|
Pflicht
| Name |
Bedeutung |
Grad |
| Debt/EBITDA |
0 |
10 |
| Gesamt: |
|
10 |
|
Wachstumsimpuls
| Name |
Bedeutung |
Grad |
| Rentabilität Revenue, % |
-53.7 |
0 |
| Rentabilität Ebitda, % |
-93.16 |
0 |
| Rentabilität EPS, % |
-95.64 |
0 |
| Gesamt: |
|
0 |
|
| Aufsicht |
Berufsbezeichnung |
Zahlung |
Geburtsjahr |
| Mr. Richard Orr Esq., J.D. |
President, CEO, Principal Financial Officer & Director |
|
1961 (64 Jahr) |
| Dr. Julien Mamet Ph.D. |
Founder, Chief Scientific Officer & Director |
|
1976 (49 Jahre) |
| Mr. William Martin |
Executive Vice President of Corporate Development & Operations |
|
|
| Ms. Dina Gonzalez |
Principal Accounting Officer & Senior VP of Finance |
|
|
| Ms. Kimberley Hebert |
Senior Director of Clinical Operations |
|
|
